LINC01194 and hepatocellular carcinoma: Using our clinically relevant murine model of HCC, we previously demonstrated that the combination of sunitinib (an FDA-approved chemotherapeutic drug for the treatment of ccRCC and GIST) with adoptive transfer of tumor antigen-specific CD8+ T cells leads to durable long term regression of established HCC tumors [84].